Next Article in Journal
Effect of miR-101 on the Proliferation and Apoptosis of Goat Hair Follicle Stem Cells
Next Article in Special Issue
Gene Expression and Epigenetic Regulation in the Prefrontal Cortex of Schizophrenia
Previous Article in Journal
Regulation of Non-Coding RNA in the Growth and Development of Skeletal Muscle in Domestic Chickens
 
 
Article
Peer-Review Record

Differentially Expressed miRNAs in Age-Related Neurodegenerative Diseases: A Meta-Analysis

Genes 2022, 13(6), 1034; https://doi.org/10.3390/genes13061034
by Ocana Noronha 1,2, Lucia Mesarosovo 1, Jasper J. Anink 1, Anand Iyer 3, Eleonora Aronica 1 and James D. Mills 1,4,5,*
Reviewer 1: Anonymous
Reviewer 2:
Genes 2022, 13(6), 1034; https://doi.org/10.3390/genes13061034
Submission received: 16 May 2022 / Revised: 2 June 2022 / Accepted: 5 June 2022 / Published: 9 June 2022
(This article belongs to the Special Issue Epigenetics in the Central Nervous System)

Round 1

Reviewer 1 Report

Dear authors, 

This is an interesting meta-analysis analyzing possible overlapping among miRNA in neurodegenerative diseases. I have some questions: 

  • Why did you decide to mix arrays with RNA sequencing? Arrays have more background noise and I am wondering if this could affect your results. Won't be better to focus only on RNA sequencing, i.e.? 
  • There are certain places where it is not clear with data you are using. I.e. "Differential expression of miRNA within proteinopathies" have you distinguished among tissues/fluid samples or have you taken all data? You should clarified that moreover, in the discussion you well pointed out that the differential expression of miRNA is tissue/fluid specific. 
  • Discussion, more literature review in connection with your results is needed. 

Thank you very much. 

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 2 Report

I thoroughly enjoyed reading the article about the meta-analyses of miRNAs in NDD. However, I have comments about improving this article -

1. Line 88 - The authors should write the complete forms of MSA, DLB, CBD, and FTLD before using the abbreviations.

2. Line 211 - Can the authors include a table to talk about the characters of these miRNAs?

3. Line 233 - Can the authors infer anything about the disease from these values of overlapping miRNAs?

4. Line 239 - hsa-miR-433 - What is the biological significance of this miRNA?

5. Line 226 - 270 - This sentence has too much information and sounds difficult for a good comparison. Can the authors break this down into 3 or 4 sentences instead?

6. Line 271 - Is there deeper molecular reasoning behind a higher number of upregulated miRNA than a lower number of downregulated miRNAs?

7. Line 284 - 285 - Are there downregulated miRNAs across all NDDs found in this group? Is there any significance to it?

8. Line 33 - Given the p-value for the Gene set enrichment, what is the ultimate significance of this study

 

 

 

 

 

 

 

 

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Round 2

Reviewer 1 Report

Dear Authors, 

The manuscript improved a lot. 

Thank you so much. 

Back to TopTop